FOMX Foamix Pharmaceuticals Ltd.

3.99
-0.19  -5%
Previous Close 4.18
Open 4.18
Price To Book 4.59
Market Cap 244,402,614
Shares 61,581,972
Volume 272,191
Short Ratio
Av. Daily Volume 709,986
Stock charts supplied by TradingView

NewsSee all news

  1. Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics

    REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today that OrbiMed Advisors

  2. Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

    REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 14, 2020 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced a coverage

  3. Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

    Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne 

  4. Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

    REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 9, 2020 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that its

  5. Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

    AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company's First Commercial Launch AMZEEQ Offers Efficacy with Low Systemic Absorption List price of $485 Competitive Against

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

PDUFA date June 2, 2020.
FMX103
Papulopustular rosacea
FDA Approval announced October 18, 2019.
FMX101
Acne
Phase 2 data released December 2015
FDX104
Acne-like rash in cancer patients
Update to be provided as it materializes.
FDX102
Impetigo
Phase 2 data due 2Q 2020.
FCD105
Acne

Latest News

  1. Foamix Announces OrbiMed's Support of Merger with Menlo Therapeutics

    REHOVOT, Israel, and BRIDGEWATER, N.J., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today that OrbiMed Advisors

  2. Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

    REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 14, 2020 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced a coverage

  3. Foamix Announces AMZEEQ™ (minocycline) Achievement of Preferred Status on Express Scripts National Preferred Formulary, One of the Largest Commercial Formularies in the U.S.

    Preferred Coverage Effective Immediately on Express Scripts National Preferred, Flex, and Basic Formularies AMZEEQ is the First FDA Approved Topical Form of Minocycline for the Treatment of Moderate to Severe Acne 

  4. Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

    REHOVOT, Israel and BRIDGEWATER, N.J., Jan. 9, 2020 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that its

  5. Foamix Announces AMZEEQ™ (minocycline) Topical Foam Available in Pharmacies Nationwide on January 13th for the Treatment of Moderate to Severe Acne

    AMZEEQ is the First FDA Approved Topical Form of Minocycline and the Company's First Commercial Launch AMZEEQ Offers Efficacy with Low Systemic Absorption List price of $485 Competitive Against

  6. Foamix Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, announced today that David Domzalski,

  7. Foamix Announces Enrollment Completion of Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (Foamix or the Company), a specialty pharmaceutical company, today announced the completion of Phase 2

  8. Foamix Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    REHOVOT, Israel, and BRIDGEWATER, N.J., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and

  9. Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

    Combination establishes a dermatology-focused company with a broad portfolio of an approved product and late-stage dermatology assetsMenlo's serlopitant for pruritus associated with prurigo nodularis ("PN") complements

  10. Foamix Announces Publication of AMZEEQ™ (minocycline) Topical Foam Long Term Safety Data for Treatment Up to 1 Year in Journal of Clinical and Aesthetic Dermatology

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (Foamix or the Company), a specialty pharmaceutical company, announced today the peer review

  11. Foamix Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 11

    REHOVOT, Israel and BRIDGEWATER, N.J., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), ("Foamix"), a clinical stage specialty pharmaceutical company focused on developing and

  12. Foamix Announces Settlement of Litigation with Teva Relating to Finacea Foam

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company, today announced that, together with

  13. Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 10, 2019 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company, today

  14. Foamix to Present Data on its Topical Product Candidates for Acne, Rosacea at 39th Annual Fall Clinical Dermatology Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company, today announced it will

  15. Foamix Pharmaceuticals to Present at the Cantor Global Healthcare Conference

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 20, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing

  16. Foamix Announces Enrollment of First Patient in Phase 2 Acne Clinical Trial for FCD105 Minocycline 3% and Adapalene 0.3% Combination Foam

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 19, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), today announced that the first patient has been enrolled in its Phase 2 clinical trial to evaluate

  17. Foamix Announces Issuance of New U.S. Patent Covering A Method of Treating Acne that Expires in 2037

    REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a clinical stage specialty pharmaceutical company focused on developing